BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 23, Pages 12628
Publisher
MDPI AG
Online
2021-11-30
DOI
10.3390/ijms222312628
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation
- (2021) Marjolijn M. Ladan et al. Cancers
- Prostate cancer and PARP inhibitors: progress and challenges
- (2021) Diego Teyssonneau et al. Journal of Hematology & Oncology
- Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
- (2021) Jun Gong et al. ONCOLOGY-NEW YORK
- The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials
- (2021) Mingyue Xia et al. Biomolecules
- Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
- (2021) Evangelia Ioannidou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
- (2021) Aruni Ghose et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
- (2021) Johann S de Bono et al. LANCET ONCOLOGY
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010.
- (2020) Evan Y. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Testing in Prostate Cancer
- (2020) Alexandra O. Sokolova et al. Current Oncology Reports
- Androgen receptor-binding sites are highly mutated in prostate cancer
- (2020) Tunç Morova et al. Nature Communications
- The incidence of myelodysplastic syndrome in patients receiving poly-ADP ribose polymerase inhibitors for treatment of solid tumors: A meta-analysis.
- (2020) Roni Nitecki et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
- (2020) Laura S. Graham et al. PLoS One
- Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
- (2020) Stergios Boussios et al. Drugs in research & development
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
- (2020) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- Mismatch Repair Pathway, Genome Stability and Cancer
- (2020) Nives Pećina-Šlaus et al. Frontiers in Molecular Biosciences
- An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
- (2020) Helen Saxby et al. Diagnostics
- Wise Management of Ovarian Cancer: On the Cutting Edge
- (2020) Stergios Boussios et al. Journal of Personalized Medicine
- Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib
- (2020) Konrad H. Stopsack EUROPEAN UROLOGY
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
- (2020) Win Topatana et al. Journal of Hematology & Oncology
- The involvement of nucleotide excision repair proteins in the removal of oxidative DNA damage
- (2020) Namrata Kumar et al. NUCLEIC ACIDS RESEARCH
- Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data
- (2020) Dawid Sigorski et al. Targeted Oncology
- PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
- (2020) Emily Nizialek et al. Cancer Management and Research
- BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
- (2020) Carlo Messina et al. Journal of Oncology
- Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
- (2020) Stergios Boussios et al. Annals of Translational Medicine
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- (2020) Nicolas Mottet et al. EUROPEAN UROLOGY
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA2 and Other DDR Genes in Prostate Cancer
- (2019) Paz Nombela et al. Cancers
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
- (2019) Piper Nicolosi et al. JAMA Oncology
- BRCAness in prostate cancer
- (2019) Natalia Bednarz-Knoll et al. Oncotarget
- Bringing prostate cancer germline genetics into clinical practice
- (2019) Sanjay Das et al. JOURNAL OF UROLOGY
- Germline and Somatic Mutations in Prostate Cancer for the Clinician
- (2019) Heather H. Cheng et al. Journal of the National Comprehensive Cancer Network
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2019) Ewa Gogola et al. CANCER CELL
- Role of the DNA damage response in prostate cancer formation, progression and treatment
- (2019) Wenhao Zhang et al. PROSTATE CANCER AND PROSTATIC DISEASES
- PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development
- (2019) Virtanen et al. Genes
- PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
- (2019) Boussios et al. Diagnostics
- Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
- (2019) Stergios Boussios et al. Diagnostics
- Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
- (2019) Elizabeth C. Page et al. EUROPEAN UROLOGY
- 846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
- (2019) W Abida et al. ANNALS OF ONCOLOGY
- LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
- (2019) M R Smith et al. ANNALS OF ONCOLOGY
- Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
- (2019) Vivek L. Patel et al. CANCER RESEARCH
- Structural basis of homologous recombination
- (2019) Yueru Sun et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
- (2019) Stergios Boussios et al. INVESTIGATIONAL NEW DRUGS
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells
- (2018) Yachen Zang et al. CANCER LETTERS
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
- (2018) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer
- (2018) Pedro Isaacsson Velho et al. PROSTATE
- DNA Damage Response in Prostate Cancer
- (2018) Matthew J. Schiewer et al. Cold Spring Harbor Perspectives in Medicine
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
- (2018) Fatima Karzai et al. Journal for ImmunoTherapy of Cancer
- Mechanisms of DNA damage, repair, and mutagenesis
- (2017) Nimrat Chatterjee et al. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
- DNA Repair in Prostate Cancer: Biology and Clinical Implications
- (2017) Joaquin Mateo et al. EUROPEAN UROLOGY
- Coordination of DNA single strand break repair
- (2017) Rachel Abbotts et al. FREE RADICAL BIOLOGY AND MEDICINE
- TOPBP1Dpb11plays a conserved role in homologous recombination DNA repair through the coordinated recruitment of 53BP1Rad9
- (2017) Yi Liu et al. JOURNAL OF CELL BIOLOGY
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- DNA mismatch repair and its many roles in eukaryotic cells
- (2017) Dekang Liu et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
- (2017) Mohammad Asim et al. Nature Communications
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences
- (2016) Lawrence A. Loeb CANCER RESEARCH
- DNA mismatch repair and the DNA damage response
- (2016) Zhongdao Li et al. DNA REPAIR
- Mismatch repair system proteins in oral benign and malignant lesions
- (2016) Gleyson Kleber do Amaral-Silva et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin
- (2016) Hana Hanzlikova et al. NUCLEIC ACIDS RESEARCH
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Genomic rearrangements in prostate cancer
- (2015) Christopher E. Barbieri et al. CURRENT OPINION IN UROLOGY
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
- (2015) Elena Castro et al. EUROPEAN UROLOGY
- Mismatch Repair
- (2015) Richard Fishel JOURNAL OF BIOLOGICAL CHEMISTRY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
- (2015) Rohit Prakash et al. Cold Spring Harbor Perspectives in Biology
- Regulators of homologous recombination repair as novel targets for cancer treatment
- (2015) Małgorzata Krajewska et al. Frontiers in Genetics
- BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
- (2014) J. E. Jaspers et al. CANCER RESEARCH
- Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
- (2014) Elizabeth K. Bancroft et al. EUROPEAN UROLOGY
- Understanding nucleotide excision repair and its roles in cancer and ageing
- (2014) Jurgen A. Marteijn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
- (2013) Nicole Clark et al. CURRENT GENOMICS
- Prediction of Clinical Drug–Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)
- (2013) Ryota Kikuchi et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- Mammalian Base Excision Repair: the Forgotten Archangel
- (2013) Grigory L. Dianov et al. NUCLEIC ACIDS RESEARCH
- Nucleotide Excision Repair in Eukaryotes
- (2013) O. D. Scharer Cold Spring Harbor Perspectives in Biology
- DNA Damage Sensing by the ATM and ATR Kinases
- (2013) A. Marechal et al. Cold Spring Harbor Perspectives in Biology
- Base Excision Repair
- (2013) H. E. Krokan et al. Cold Spring Harbor Perspectives in Biology
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- The role of BRCA1 and BRCA2 in prostate cancer
- (2012) Elena Castro et al. ASIAN JOURNAL OF ANDROLOGY
- ETS rearrangements in prostate cancer
- (2012) Mark A Rubin ASIAN JOURNAL OF ANDROLOGY
- Germline BRCA1 mutations increase prostate cancer risk
- (2012) D Leongamornlert et al. BRITISH JOURNAL OF CANCER
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
- (2012) Katharina Schlacher et al. CANCER CELL
- Polymorphisms in base-excision & nucleotide-excision repair genes & prostate cancer risk in north Indian population
- (2012) RamaDevi Mittal et al. INDIAN JOURNAL OF MEDICAL RESEARCH
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Inactivation of ATM/ATR DNA Damage Checkpoint Promotes Androgen Induced Chromosomal Instability in Prostate Epithelial Cells
- (2012) Yung-Tuen Chiu et al. PLoS One
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
- (2011) Katharina Schlacher et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Common Gene Rearrangements in Prostate Cancer
- (2011) Mark A. Rubin et al. JOURNAL OF CLINICAL ONCOLOGY
- The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
- (2010) Michael R. Lieber Annual Review of Biochemistry
- Therapeutic Targeting of the DNA Mismatch Repair Pathway
- (2010) S. A. Martin et al. CLINICAL CANCER RESEARCH
- BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
- (2010) N. Bednarz et al. CLINICAL CANCER RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Base excision repair genes XRCC1 and APEX1 and the risk for prostate cancer
- (2010) H. Kuasne et al. MOLECULAR BIOLOGY REPORTS
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- Brca2 and Trp53 Deficiency Cooperate in the Progression of Mouse Prostate Tumourigenesis
- (2010) Jeffrey C. Francis et al. PLoS Genetics
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
- (2009) F. Colotta et al. CARCINOGENESIS
- Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor-Dependent Manner
- (2009) H. Schayek et al. CLINICAL CANCER RESEARCH
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen regulation of the androgen receptor coregulators
- (2008) Alfonso Urbanucci et al. BMC CANCER
- Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9
- (2008) Loredana Moro et al. CANCER SCIENCE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now